CLCN2

Chloride channel protein 2 · P51788 · CLCN2 on Sugi Atlas →

7,179 patent compounds predicted against CLCN2, 4,404 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Meclofenamic Acid (SCHEMBL106)	0.77	9/20
Meclofenamic Acid (SCHEMBL1320065)	0.75	9/20
Meclofenamic Acid (SCHEMBL436190)	0.65	9/20
Meclofenamic Acid (SCHEMBL437889)	0.61	9/20
Meclofenamic Acid (SCHEMBL1538458)	0.57	9/20
SCHEMBL374641	0.70	7/20
SCHEMBL670482	0.51	7/20
SCHEMBL3064448	0.60	6/20
Niflumic Acid (SCHEMBL2472623)	0.63	5/20
Clofenamic Acid (SCHEMBL1477650)	0.59	5/20
SCHEMBL374772	0.54	5/20
SCHEMBL3364457	0.52	5/20
SCHEMBL1549395	0.57	4/20
SCHEMBL108571	0.44	4/20
SCHEMBL1495357	0.41	4/20
SCHEMBL909851	0.35	4/20
SCHEMBL2760397	0.63	3/20
Terofenamate (SCHEMBL49245)	0.60	3/20
Terofenamate (SCHEMBL250036)	0.57	3/20
SCHEMBL2739334	0.56	3/20

Clinical trials — most relevant to CLCN2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis	PHASE3	COMPLETED
Stem Cell Gene Therapy for Cystinosis	PHASE1/PHASE2	COMPLETED
Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects	PHASE1/PHASE2	COMPLETED
Secretin in Ex-situ Liver Perfusion	PHASE1/PHASE2	ENROLLING_BY_INVITATION
Hydroxychloroquine in Cystic Fibrosis	PHASE1	COMPLETED
Regional Monitoring of CF Lung Disease	EARLY_PHASE1	RECRUITING
Comparison Between Ultra-low-dose Computed Tomography and Lung MRI in Cystic Fibrosis	nan	COMPLETED
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis	nan	COMPLETED
Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls	nan	COMPLETED
Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis	nan	COMPLETED
Energy Balance and Weight Gain With Ivacaftor Treatment	nan	COMPLETED
A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis	nan	NOT_YET_RECRUITING
Sweat Response, Sweat Composition and Thermoregulatory Response to Exercise in Heat in Adults With Cystic Fibrosis on Modulator Therapy.	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis	nan	RECRUITING
Assessing Mucociliary Clearance and Airway Liquid Volume in the CF Airway	nan	COMPLETED
Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae	nan	ACTIVE_NOT_RECRUITING
Comparative Effects of Mechanical and Manual Airway Clearance Techniques in Cystic Fibrosis	nan	NOT_YET_RECRUITING
The Role of Biomarkers in Inherited Cardiac Conditions	nan	WITHDRAWN
Gene Modifiers of Cystic Fibrosis Lung Disease	nan	ACTIVE_NOT_RECRUITING
Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy	nan	COMPLETED
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study	nan	COMPLETED
Evaluating Sensations of Breathlessness in Patients With Cystic Fibrosis	nan	COMPLETED
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics Pilot Study	nan	COMPLETED
The Effect of Adding Lubiprostone to Standard Large-Volume PEG-ELS on The Quality of Inpatient Colonoscopy Preparation	nan	WITHDRAWN
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis	nan	UNKNOWN
Performance and Patient Acceptance of a Commercially Available Beverage as Compared to an Oral Glucose Solution for Oral Glucose Tolerance Tests in Cystic Fibrosis (CF) Patients Who Are Screened for CF-related Diabetes.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CLCN2 binder may also engage these)

Protein	Name	Similarity
Q9R0A1	—	0.999	Q9R0A1 →
P35525	—	0.999	P35525 →
P51789	—	0.999	P51789 →
Q9WU45	—	0.996	Q9WU45 →
O35454	—	0.980	O35454 →
Q9TT16	—	0.978	Q9TT16 →
P51797	—	0.977	P51797 →
Q64347	—	0.977	Q64347 →
P51803	—	0.976	P51803 →
P51800	—	0.975	P51800 →
P35524	—	0.974	P35524 →
Q06393	—	0.973	Q06393 →
Q9WUB7	—	0.973	Q9WUB7 →
P51804	—	0.973	P51804 →
P35523	—	0.972	P35523 →
P51801	—	0.971	P51801 →
Q9WUB6	—	0.971	Q9WUB6 →
Q9H8M5	—	0.970	Q9H8M5 →
P0C588	—	0.970	P0C588 →
A0JPA0	—	0.970	A0JPA0 →
Q9MZT1	—	0.970	Q9MZT1 →
P51802	—	0.969	P51802 →
Q9W701	—	0.968	Q9W701 →
Q6P4Q7	—	0.968	Q6P4Q7 →
E9Q4Z2	—	0.968	E9Q4Z2 →
Q3TWN3	—	0.967	Q3TWN3 →
Q5U2P1	—	0.966	Q5U2P1 →
O97704	—	0.966	O97704 →
A1L3P4	—	0.965	A1L3P4 →
SLC34A1	Sodium-dependent phosphate transport protein 2A	0.965	landscape →